In order to use Auger-electron therapeutic effects in CD20 antigen targeting in lymphomas, Mabthera™ (rituximab) N-succinimidyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-acetic acid (DOTA-NHS) and ccDTPA separately. Conjugated-Rituximab was obtained by the addition of 1 ml of a rituximab pharmaceutical solution (5 mg/ml, in phosphate buffer, pH=7.8) to a glass tube pre-coated with freshly prepared DOTA-NHS or ccDTPA (0.01-0.1 mg) at 25°C. Radiolabeling was performed at 37°C in 3h
Introduction
Several studies of radiolabeled anti-CD20 monoclonal antibodies at nonmyeloablative doses in treating B-cell NHL have been reported, and several are in progress. The agents for which most data are available are 131 I-tositumomab (Bexxar) and yttrium 90 Y-ibritumomab tiuxetan (Zevalin). These studies have reported response rates of 25% to 40% with median response duration of 6 to 18 months in most studies and some very durable responses of more than 5 years [1] [2] [3] [4] . In some studies, rituximab has been labeled for metabolism and localization of CD20 antigens throughout the body and/or penetration of the antibody to specific organs [5] .
In order to obtain an anti-CD20 conjugate for use in diagnostic/therapeutic studies, the 111 In-labeled antibody was prepared as a model of metal chelated immunoconjugate for preliminary dosimetric and biodistribution studies in rats.
As bi-functional ligands, N-succinimidyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (3, DOTA-NHS) [6] and freshly prepared ccDTPA were used.
DOTA ligand has already shown good biological performance when used in protein conjugation of various radioisotopes such as Ga-68 [7] , Ga-66 [8] , Ac-225 [9] , Lu-177 [10] and lead radioisotopes [11] .
Based on recent experiences on the preparation of radiometal-labeled rituximab for lymphoma imaging [12] , we were interested in the preparation of an antiCD-20 immunoconjugate involving a cyclotron-produced radionuclide, i. e. In-111 (HL:67 h, major photopeak at 172 keV).
A precise labeling strategy was employed using freshly-prepared DOTA-NHS and ccDTPA and optimized radiolabeling methods for developing highly reactive conjugated anti-CD20 for radiometal studies has been has been introduced for diagnosis and therapy purposes.
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Results and discussion
Preparation and structure confirmation of DOTA NHS
Various solvents can be used in the esterification reaction of DOTA and NHS, such as DMF, DMSO, etc. Due to the high boiling point of such solvents and the possibility of protein denaturing caused by these solvents, we tried to use dichloromethane based on the previous reports for DCC-mediated conjugation reactions [13] . This reaction is performed at room temperature and can be done The formation of mono-succinimidyl ester at R f of 0.36 was observed. In case of longer reaction times another species at R f =0.56-0.6 can be observed and is related to di-succinimidyl ester. All reactants remain at the R f of 0.0-0.1. give very distinguishable Rfs in contrast to the others respectively 0.3, 0.5, 0.9 and 0.9. Due to the size and charge of the protein (≈150,000 D), 111 In-DOTA-rituximab remains at the origin in all systems used.
Conjugation of rituximab with
In HPLC studies using reverse phase column in 1mMDTPA as eluent. The fast eluting component (3.4 min) was shown to be a mixture of free 111 In and 111 InDTPA.
Both compounds are ionic, so they are eluted at the same retention time. The radiolabeled protein was finally washed out at 15.86 minutes (Figure 2. ).
Due to UV absorbance of DTPA moiety, the UV detector chromatogram can not be used for chemical purity determination, however using free DTPA and In-111
for control studies, it was shown that 98% of present DTPA at the reaction pH will form 111 In-DTPA species which can be analyzed by flow scintillation analyzer.
Assuming the only impurity in whole process would be DTPA. In the production 
Stability of Radiolabeled Protein in presence of human serum in vitro
After incubation of 111 In-DOTA-rituximab with freshly prepared human serum at described conditions in the methods, 96-98% of the radioactivity eluted at the same fraction as 111 In-DOTA-rituximab, using size exclusion chromatography. Thus, there was no evidence for either degradation or transchelation of 111 In to other serum proteins over a time period consistent with the normal blood clearance time of rituximab.
Protein integrity test using SDS-Polyacrylamide Gel Electrophoresis
In order to demonstrate the integrity of the protein after conjugation and radiolabeling gel electrophoresis was performed on the SDS PAGE gels using 16% bisacrylamide gel. The loaded samples were Rituximab commercial sample, DOTA- rituximab and radiolabeled protein samples a week after the experiment while kept in the fridge. The 3 samples were showed to have similar pattern of migration in the gel electrophoresis.
Interestingly the SDS PAGE results were checked with a reported commercial Rituximab sample [16] . Figure 5 . shows the SDS-PAGE patterns for both DOTA and DTPA conjugates in contrast to starting Rituximab sample and radiolabeled immunoconjugates. In-DOTA-rituximab (4), DTPA-rituximab conjugate (5), 111 In-DOTArituximab (7) in contrast to in house-made standard ladder (1).
Biodistribution studies
The animals were sacrificed by ether asphyxiation at selected times after injection (24, 48 and 72h for DTPA conjugate and 2, 24 and 48h for DOTA conjugate). Dissection began by drawing blood from the aorta, followed by collecting blood, heart, spleen, kidneys, liver, intestine, stomach, lung and skin At two hours post injection, the activity is mainly in the blood which is in agreement with the other reported labeled antibodies [14] , while the activity of the stomach, muscle, intestine and spleen is rather low. and rats has not been demonstrated. On the other hand, rituximab natural binding was found on lymphoid cells in the thymus, the white pulp of the spleen, and a majority of B-lymphocytes in peripheral blood and the lymph nodes in human being [16] , this has been observed in our studies on the normal rats as well.
In some rats tested, accumulation in the lungs was observed. At the beginning it was concluded that this accumulation is caused by the non-specific immigration of the lymphocytes to the possibly infected bronchi of the objects which the infection.
But the infection was not later confirmed by the lab tests post-mortem. Interestingly, we found reports of severe pulmonary reactions with pulmonary infiltrates or edema Preparation, Quality Control and Biodistribution Studies of … 161 in human casued by anti-CD20. Acute symptoms appear within 1-2 hours of the initiation of the 1st infusion [17] . Rituximab was a pharmaceutical sample purchased from Roche Co. and was used without further purification. Radio-chromatography was performed by counting polymer-backed silica gel paper and/or C 18 thin layer sheets using a thin layer chromatography scanner, Bioscan AR2000. Analytical HPLC to determine the specific activity was performed by a Shimadzu LC-10AT, armed with two detector systems, flow scintillation analyzer (Packard-150 TR) and UV-visible (Shimadzu)
Experimental
using Whatman Partisphere C-18 column 250 x 4.6 mm, Whatman Co. NJ, USA.
Calculations were based on the 172 keV peak for 111 In. All values were expressed as mean ± standard deviation (Mean± SD) and the data were compared using student T-test.
Statistical significance was defined as P<0.05. Animal studies were performed in accordance with the United Kingdom Biological Council's Guidelines on the Use of Living Animals in Scientific Investigations, 2nd edn.
Production and quality control of 111 In-InCl 3 solution
Cadmium electroplating over a copper surface was performed according to previously reported method [18] . 111 In-indium chloride was prepared by 20 MeV proton bombardment of the natural Cd target [13] . The presence of copper and cadmium impurities in the final solution was checked using acidic dithizone solution and alkaline dimethylglyoxime and NaK tartrate respectively according to the procedure [19, 20] .
Conjugation of cyclic DTPA di-anhydride with rituximab
The chelator diethylenetriamine penta-acetic acid dianhydride was conjugated wth the Rituximab using a small modification of the well-known cyclic anhydride method [21] . 
Conjugation of NHS-DOTA with the rituximab
The chelator N-succinimidyl- 1,4,7,10-tetraazacyclododecane-1,4,7,10- tetraacetic acid (DOTA-NHS) prepared above, was conjugated to the antibody using a small modification of the DOTA-NHS method [23] . The residue mixture above was evaporated under a flow of N 2 gas in a glass tube producing a thin film coat of DOTA-NHS. The commercially available antibody Rituximab ® (5mg/ml, pH.7.8, 0.5 ml) was added to the coated glass tube while gently mixed at room temperature for 30 s. The mixture was then incubated in a water bath at 25°C for 15-18 hours.
This conjugation mixture was then passed through a Sephadex G-50 column (2 × 15 cm, prepared by soaking 2g of the resin in 50 ml of Milli-Q ® water overnight)
separately and one-milliliter fractions were collected and checked for the presence of protein using UV absorbance at 280 nm or visible folin-phenol colorimetric assay.
The fraction containing the highest concentration of the immunoconjugate was chosen and kept at 4°C and for radiolabeling.
Radiolabeling of the antibody conjugate with 111 In
The antibody conjugate was labeled using an optimization protocol according to the literature [24] . showed the presence of protein, which fraction 6 was used in the other experiments (n=3).
Preparation of 111 In-DOTA for control studies
For control studies, 111 In-DOTA was prepared for R f and retention time studies in chromatographic methods [19] . System II: From the final product, 5 µl was applied to a silica-impregnated glass fiber sheet followed by developing in 0.9% NaCl for 5 min. Radioactivity was determined by a chromatography scanner equipped with an HPGe crystal. 111 In-DOTA will move to the front, the 111 In-labelled monoclonal antibody remains at the starting position [9] .
System III: Another system was performed on silica-impregnated glass fibre sheets. From the final product, 5 µl was applied to the ITLC strip that was 
High performance liquid chromatography
HPLC was performed on the final preparation using acetate buffer solution (50 mM pH. 5.5) as eluent (flow rate: 1ml/min pressure: 130 KgF/cm 2 ) for 20 min in order to elute low molecular weight components.
Radiolabeled antibody was eluted using a gradient of the latter solution (100 to 0%) and citrate buffer solution (50mM, pH.4, 0 to 100%) using reverse stationary phase. Any remaining free In 3+ cation can be complexed with citrate anion; however pre-complexed In-DTPA-rituximab was not challenged with the addition of citrate chelate [25] .
SDS-Polyacrylamide Gel Electrophoresis
The radioimmunoconjugates were analyzed for integrity by SDSpolyacrylamide gel electrophoresis (SDS-PAGE). The radiolabeled mAb was evaluated with and without reduction by 2-mercaptoethanol. Approximately 200,000 cpm of each preparation was applied per lane and the 4-20% polyacrylamide were run according to the method of Laemmli [26] .
Stability testing of the radiolabeled compound in final formulation
Stability of 111 In-DOTA-rituximab in PBS was determined by storing the final solution at 4°C for 14 days and performing frequent ITLC analysis to determine radiochemical purity. The stability of the conjugated DOTA-rituximab stored at −20 °C for more than 3 months was also investigated. ITLC analysis of the conjugated product was performed to monitor for degradation products or other impurities. After subsequent 111 In-labeling of the stored conjugated product, both labeling efficiency and radiochemical purity were determined.
Stability testing of the radiolabeled compound in presence of human serum
Radiolabel stability was assessed by size exclusion chromatography on a Sepharose column (1 × 30 cm). The column was equilibrated with PBS and eluted at a flow rate of 0.5 mL/min at room temperature; 1 mL fractions were collected.
Biodistribution of 111 In-radioimmunoconjugates to normal rats
To determine its biodistribution, 111 In-DOTA/DTPA-rituximab was administered to normal rats. A volume (50-100 μl) of final 111 In-DOTA/DTPA-rituximab solution containing 20±5 μCi radioactivity was injected intravenously to rats through their tail vein. The animals were sacrificed at the exact time intervals (2-48 h), and the specific activity of different organs was calculated as percentage of injected dose per gram using a radiometer.
Conclusion
Two separate rituximab conjugates were prepared and their behaviour in radiolabeling, quality control radiochemical purity were compared. For control studies 111
In-DOTA was prepared and was checked using RTLC and HPLC. 
